Area postrema syndrome: a neurological presentation of nausea, vomiting and hiccups

Ka Hong Chan 1, Galina Vorobeychik 2

DESCRIPTION
A 44-year-old, previously healthy, Asian woman presented with a 1-month history of daily, intractable nausea, vomiting, hiccups and a 7 kg weight loss. She had persistent dry heaves, with food triggering vomiting. She had no neurological symptoms, including a normal examination and subsequent visual evoked potentials. Thorough medical investigations including haematology, biochemistry (including C-reactive protein) and autoimmune workup, CT and ultrasound abdominal imaging, as well as upper endoscopy were all normal, except for a positive anti-Sjögren’s-syndrome-related antigen (AQP4-IgG) and autoantibodies against myelin oligodendrocyte glycoprotein (MOG, anti-MOG antibodies were negative, her classical gastrointestinal symptoms combined with her MRI scan was highly suggestive of area postrema syndrome (APS), a characteristic presentation of neuromyelitis optica (NMO).1, 2 Following treatment with pulse methylprednisolone, her symptoms recovered completely with subsequent weight recovery. This was followed by rituximab maintenance therapy with no recurrences for over 9 months.

NMO is an autoimmune, demyelinating disorder characterised by AQP4-IgG antibodies that more commonly affects women. Classical NMO is typically recognised by recurrent attacks of optic neuritis or transverse myelitis. Yet, as with our case, approximately 30% of patients can present with isolated brainstem syndromes, with the most common

Box 1 International consensus on the diagnostic criteria of neuromyelitis optica spectrum disorders (NMOSD). Adapted from 9. AQP4: aquaporin-4, IgG: immunoglobulin G, LETM: longitudinally extensive transverse myelitis lesions

- Positive AQP4-IgG
- Exclusion of other diagnoses

Diagnostic criteria for NMOSD without or unknown AQP4-IgG:
1. At least two clinical characteristics occurring as a result of one or more clinical attacks and meeting all the below:
   - At least one clinical characteristic must be optic neuritis, acute myelitis with LETM or area postrema syndrome
   - Dissemination in space (two or more different core clinical characteristics)
   - Fulfilment of additional MRI criteria, as applicable (see below)
2. Negative tests AQP4-IgG using the best available detection method, or testing unavailable
3. Exclusion of other diagnoses

Core clinical characteristics:
1. Optic neuritis
2. Acute myelitis
3. Area postrema syndrome
4. Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

Additional MRI requirements for NMOSD without or unknown AQP4-IgG:
1. Acute optic neuritis requires brain MRI showing (a) normal findings or only nonspecific white matter lesions, OR (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium-enhancing lesion extending over > ½ optic nerve length or involving optic chiasm
2. Acute myelitis requires associated intramedulary MRI lesion extending ≥3 contiguous segments (LETM) OR ≥3 contiguous segments of focal spinal cord atrophy in patients with history compatible with acute myelitis
3. Area postrema syndrome requires associated dorsal medulla/area postrema lesions

Figure 1 MRI T2 FLAIR sequence demonstrating bilateral lesions in the area postrema (highlighted by arrows) in the (A) sagittal and (B) transverse planes. Hyperintensity in this area at the level of the medulla oblongata with associated intractable nausea and vomiting is consistent with a diagnosis of area postrema syndrome.

1Department of Medicine, Division of General Internal Medicine, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada
2Department of Medicine, Division of Neurology, The University of British Columbia Faculty of Medicine, Burnaby, British Columbia, Canada

Correspondence to Dr Galina Vorobeychik, Galina.Vorobeychik@fraserhealth.ca

Accepted 24 September 2020

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Chan KH, Vorobeychik G. BMJ Case Rep 2020;13:e238588. doi:10.1136/bcr-2020-238588
symptoms being intractable nausea, vomiting and hiccups due to APS.²,³ This has been shown to be more common in the Asian and African-American populations.⁴

APS is characterised by lesions found in the area postrema (AP), an area rich in AQP4 receptors. Anatomically, AP is a vascular structure found in the floor of the fourth ventricle, and acts as the vomiting centre by combining chemical and neural inputs from blood and brainstem, respectively.⁵ The leaky blood-brain barrier found here makes it accessible to AQP4-IgG, and is thought to represent an early phase of NMO.³ Unlike spinal and optic lesions of classic NMO, lesions in the AP usually demonstrate more inflammation than demyelination and necrosis, explaining the potential for complete recovery following treatment.¹,⁴ Binding of IgG to AQP4 in the AP lacks immunoreactivity to activate the complement system, and instead, causes receptor downregulation. The resulting alterations to neurotransmitter homeostasis trigger vomiting.¹ Rarely in adults, external mass effect (eg, tumours) can also affect this area.⁶

Although the presence of anti-SSA is associated with serum AQP4-IgG positivity in the Asian population, it was negative in our case. Interestingly, only 14% of patients presenting with APS are.¹ MOG positivity is also rare.⁸ T2 lesions within AP is characteristic of NMO as per the diagnostic criteria (box 1).⁹ Early recognition of this disease allows for prompt treatment that may reduce the morbidity and mortality of this severe syndrome, with 50% of patients having visual or ambulatory impairments within 5 years.³ Acute attacks are typically treated with pulse methylprednisolone for 3–5 days or plasma exchange. Maintenance therapy is initiated subsequently to reduce relapses. Azathioprine and rituximab followed by mycophenolate mofetil are the best studied, with some evidence suggesting rituximab to be the most effective.¹⁰

**REFERENCES**


**Learning points**

► Area postrema syndrome (APS) is part of the neuromyelitis optica spectrum of disorders, and can present solely with nausea, vomiting and hiccups and no neurological symptoms.

► Many cases of APS can present atypically with aquaporin-4 antibody negativity, with lesions on MRI in the area postrema, an emetogenic centre targeted by the antibodies, being highly suggestive of this disorder.

► Prompt treatment with steroids followed by maintenance therapy with rituximab can reduce the severe neurological morbidity and mortality of this disorder.

**Box 1**

4. Acute brain stem syndrome requires associated periependymal brainstem lesions

Box originally from Wingerchuk et al.⁹